Saturday 28 June 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • AstraZeneca continues legal battles over Forxiga in Russia

AstraZeneca continues legal battles over Forxiga in Russia

Pharmaceutical
1 May 2025

The Russian drugmaker Akrikhin has filed a lawsuit against UK pharma major AstraZeneca (LSE: AZN) to the Moscow Intellectual Property Court asking to recognize its right to use formulas from two patents of Astra Zeneca for production of Forxiga (dapagliflozin), a drug for the treatment of diabetes and cardiovascular diseases, The Pharma Letter’s local correspondent reports.

As part of the lawsuit, the Russian company has also demanded to oblige Astra Zeneca “to refrain from creating obstacles during the launch of Forxiga into the civil market in Russia.

In the meantime, a spokesman of AstraZeneca in an interview with the Russian newswire RIA Novosti said that the company will continue to defend its intellectual property rights.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Generics
AstraZeneca defends patent for Forxiga in Russia
4 July 2024
Pharmaceutical
Akrikhin expands deal with Merck & Co
8 August 2013


Company News Directory



Companies featured in this story

More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Formycon increases bond volume following oversubscription
Biosimilars
Formycon increases bond volume following oversubscription
28 June 2025
Pharmaceutical
Arbutus regains global rights to imdusiran following Qilu exit
27 June 2025
Biotechnology
Calico signs $571 million licensing deal with Mabwell for IL-11 drug
27 June 2025
Pharmaceutical
Bayer extends long-standing Tsinghua University partnership
27 June 2025
Biotechnology
New data for nusinersen underscore Biogen’s commitment to SMA
27 June 2025
Pharmaceutical
CDC’s ACIP meets, stressing ‘no pre-determined ideas’
27 June 2025
Biotechnology
BeOne Medicines showcases oncology pipeline
27 June 2025

Company Spotlight

A data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases.




More Features in Pharmaceutical

Arbutus regains global rights to imdusiran following Qilu exit
27 June 2025
Bayer extends long-standing Tsinghua University partnership
27 June 2025
CDC’s ACIP meets, stressing ‘no pre-determined ideas’
27 June 2025
Chugai files for additional tumor-agnostic indication of Alecensa
27 June 2025


The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze